4.5 Article Proceedings Paper

Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia

Journal

PHARMACOTHERAPY
Volume 25, Issue 12, Pages 1736-1745

Publisher

WILEY
DOI: 10.1592/phco.2005.25.12.1736

Keywords

anticoagulation; dose; bleeding; platelet-aggregation test; heparin platelet factor 4; enzyme-linked immunosorbent assay; H-PF4 ELISA; serotonin-release assay

Ask authors/readers for more resources

Study Objective. To evaluate diagnostic tests for heparin-induced thrombocytopenia (HIT), a serious drug reaction that can occur in patients receiving heparin, and to evaluate treatment with direct thrombin inhibitors-the only initial drug therapy that decreases the risk of thromboembolism associated with immune-mediated HIT. Design. Retrospective cohort study. Setting. University teaching hospital. Subjects. Patients with HIT treated with argatroban or lepirudin between January 1, 2000, and December 31, 2003. Measurements and Main Results. Patients were assessed for dosage and duration of argatroban or lepirudin therapy, HIT diagnostic tests, and clinically significant adverse events. Thirty-four patients received argatroban, 42 received lepirudin. Mean +/- SD doses of argatroban and lepirudin were 1.2 +/- 0.9 pg/kg/minute and 0.09 +/- 0.11 mg/kg/hour, respectively; both were 40% lower than the recommended doses. Mean duration of therapy was 10 +/- 9 days. Supratherapeutic activated partial thromboplastin times were observed in 30 (39%), 10 (13%), and six (8%) of 76 patients on days 1, 2, and 3, respectively (p<0.0001). Clinically significant bleeding occurred in 6% of patients receiving argatroban and in 5% of those receiving lepirudin (p=0.99); all patients had an activated partial thromboplastin time of longer than 100 seconds. Although platelet-aggregation tests were ordered in 55 (72%) of 76 patients, they were not useful in 16 (29%) because of equivocal or contradictory results. Conclusion. Due to supratherapeutic activated partial thromboplastin times, our patients often required doses of argatroban and lepirudin lower than those usually recommended. Thus, direct thrombin inhibitors should be started at low initial doses and titrated to target activated partial thromboplastin times to achieve appropriate efficacy and to avoid increasing the risk of bleeding. Platelet-aggregation tests were least useful for evaluating HIT. Appropriate diagnostic strategies should be used to avoid unnecessary drug use.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available